Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

Cited In for PubMed (Select 17105829)

1.

Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter.

Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, Katz JL.

Drug Alcohol Depend. 2015 Feb 1;147:1-19. doi: 10.1016/j.drugalcdep.2014.12.005. Epub 2014 Dec 18.

PMID:
25548026
2.

Treatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: a randomized, double blind, placebo-controlled human laboratory study.

Verrico CD, Haile CN, Mahoney JJ 3rd, Thompson-Lake DG, Newton TF, De La Garza R 2nd.

Drug Alcohol Depend. 2014 Aug 1;141:72-8. doi: 10.1016/j.drugalcdep.2014.05.008. Epub 2014 May 28.

PMID:
24928479
3.

2-isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter.

Hiranita T, Wilkinson DS, Hong WC, Zou MF, Kopajtic TA, Soto PL, Lupica CR, Newman AH, Katz JL.

J Pharmacol Exp Ther. 2014 May;349(2):297-309. doi: 10.1124/jpet.113.212738. Epub 2014 Feb 11. Erratum in: J Pharmacol Exp Ther. 2014 Jun 1;349(3):534.

4.

Monoamine transporter inhibitors and substrates as treatments for stimulant abuse.

Howell LL, Negus SS.

Adv Pharmacol. 2014;69:129-76. doi: 10.1016/B978-0-12-420118-7.00004-4. Review.

5.

Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice.

O'Tousa DS, Warnock KT, Matson LM, Namjoshi OA, Linn MV, Tiruveedhula VV, Halcomb ME, Cook J, Grahame NJ, June HL.

Addict Biol. 2015 Mar;20(2):236-47. doi: 10.1111/adb.12100. Epub 2013 Oct 13.

PMID:
24118509
6.

Identifying the molecular basis of inhibitory control deficits in addictions: neuroimaging in non-human primates.

Groman SM, Jentsch JD.

Curr Opin Neurobiol. 2013 Aug;23(4):625-31. doi: 10.1016/j.conb.2013.03.001. Epub 2013 Mar 22.

7.

PET studies in nonhuman primate models of cocaine abuse: translational research related to vulnerability and neuroadaptations.

Gould RW, Duke AN, Nader MA.

Neuropharmacology. 2014 Sep;84:138-51. doi: 10.1016/j.neuropharm.2013.02.004. Epub 2013 Feb 28. Review.

PMID:
23458573
8.

Individual differences and social influences on the neurobehavioral pharmacology of abused drugs.

Bardo MT, Neisewander JL, Kelly TH.

Pharmacol Rev. 2013 Jan 23;65(1):255-90. doi: 10.1124/pr.111.005124. Print 2013 Jan. Review.

9.

Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter.

Cameron KN, Kolanos R, Solis E Jr, Glennon RA, De Felice LJ.

Br J Pharmacol. 2013 Apr;168(7):1750-7. doi: 10.1111/bph.12061.

10.

Novel C-1 substituted cocaine analogs unlike cocaine or benztropine.

Reith ME, Ali S, Hashim A, Sheikh IS, Theddu N, Gaddiraju NV, Mehrotra S, Schmitt KC, Murray TF, Sershen H, Unterwald EM, Davis FA.

J Pharmacol Exp Ther. 2012 Nov;343(2):413-25. doi: 10.1124/jpet.112.193771. Epub 2012 Aug 15.

11.

Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology.

Warnock KT, Yang AR, Yi HS, June HL Jr, Kelly T, Basile AS, Skolnick P, June HL.

Pharmacol Biochem Behav. 2012 Nov;103(1):111-8.

12.

Agonist replacement therapy for cocaine dependence: a translational review.

Rush CR, Stoops WW.

Future Med Chem. 2012 Feb;4(2):245-65. doi: 10.4155/fmc.11.184. Review.

13.

Simultaneous measurement of extracellular dopamine and dopamine transporter occupancy by cocaine analogs in squirrel monkeys.

Kimmel HL, Nye JA, Voll R, Mun J, Stehouwer J, Goodman MM, Votaw JR, Carroll FI, Howell LL.

Synapse. 2012 Jun;66(6):501-8. doi: 10.1002/syn.21536. Epub 2012 Mar 16.

14.

Further structure-activity relationship studies on 8-substituted-3-[2-(diarylmethoxyethylidenyl)]-8-azabicyclo[3.2.1]octane derivatives at monoamine transporters.

Cararas SA, Izenwasser S, Wade D, Housman A, Verma A, Lomenzo SA, Trudell ML.

Bioorg Med Chem. 2011 Dec 15;19(24):7551-8. doi: 10.1016/j.bmc.2011.10.028. Epub 2011 Oct 18.

15.

Influence of chronic dopamine transporter inhibition by RTI-336 on motor behavior, sleep, and hormone levels in rhesus monkeys.

Andersen ML, Sawyer EK, Carroll FI, Howell LL.

Exp Clin Psychopharmacol. 2012 Apr;20(2):77-83. doi: 10.1037/a0026034. Epub 2011 Oct 24.

16.

Nonhuman primate models of addiction and PET imaging: dopamine system dysregulation.

Gould RW, Porrino LJ, Nader MA.

Curr Top Behav Neurosci. 2012;11:25-44. doi: 10.1007/7854_2011_168.

17.

Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.

Horton DB, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP.

J Pharmacol Exp Ther. 2011 Oct;339(1):286-97. doi: 10.1124/jpet.111.184770. Epub 2011 Jul 21.

18.

Neuroimaging and drug taking in primates.

Murnane KS, Howell LL.

Psychopharmacology (Berl). 2011 Jul;216(2):153-71. doi: 10.1007/s00213-011-2222-7. Epub 2011 Mar 1. Review.

19.

Nonhuman primate positron emission tomography neuroimaging in drug abuse research.

Howell LL, Murnane KS.

J Pharmacol Exp Ther. 2011 May;337(2):324-34. doi: 10.1124/jpet.108.136689. Epub 2011 Feb 11.

20.

In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat.

Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB.

J Pharmacol Exp Ther. 2011 Apr;337(1):218-25. doi: 10.1124/jpet.110.176271. Epub 2011 Jan 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk